Lifitegrast · LIFITEGRAST 50 mg/mL · For Solution · Ophthalmic · Aurobindo Pharma Limited
NDC 59651-0450-60 · 60 POUCH in 1 CARTON / 5 AMPULE in 1 POUCH / .2 mL in 1 AMPULE · ANDA · View full market →
Only one company currently supplies this market — there is no backup if it stumbles. One of its named manufacturing plants, Eugia Pharma Specialities Limited, failed FDA inspectionwithin the last two years — the agency’s most serious outcome.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Not scored — fragility is computed for NADAC-priced NDCs.
OAI inspection at a producing facility (24 months) · sole-source market · price up 3% YoY
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Aurobindo Pharma Limited | LIFITEGRAST 50 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Lifitegrast — NDC 59651-0450-60," retrieved September 3, 2026, https://drugdashboards.com/drug/59651045060.
Free to cite with attribution — see how the data is put together.